Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
  2. News
  3. implant construct
Show results for
Products
Services
Companies
News
Articles
Downloads
Refine by
Date

Implant Construct Articles & Analysis

1 news found
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells HiT works as well, or better than, a TRuC construct targeting mesothelin in preclinical studies Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported preclinical data from its HiT targeting ...

ByAdaptimmune LLC

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you